ACELYRIN, INC.’s Post

💰✨ Plan your event's financial roadmap with care! Don't forget to budget for surprises! Stay flexible to ensure a successful event. Call us at 877-892-4500 or visit www.personalsommeliers.com #EventBudget #FinancialAllocation #EventPlanning #ExpenseManagement #BudgetFlexibility #EventSuccess #EventOrganization #EfficientPlanning #EventFinance #BudgetPlanning #EventManagement #ExpenseAllocation #FinancialStrategy

Risk pool governing body members regularly review and discuss overall pool financial solvency and financial performance. Dive into best practices for fiduciary and financial solvency during Carrie Rice and Elyssa Nagle's session at the 2024 AGRiP (Association of Governmental Risk Pools) Governance Conference. Learn how to review and read financial statements, address key internal controls, acknowledge the link between actuarial reports and a pool's financial statements, and more: https://ow.ly/vn5E50QIShT #AGRiPGovernance #JLInsights #FinancialSolvency #RiskManagement #GovernmentalRiskPool

Within the financial services sector, conferences, investor days and webinars alike are expected to deliver a professional, seamless and insightful experience for audiences. We've collated a checklist for planning events that will ensure your delegates come away feeling like their time was well invested. Learn more here → https://lnkd.in/emd2xjzx #CorporateEvents #EventProduction #FinanceEvent #ConferencePlanning #FinancialMarketing

If you are at the First Financial Resources Symposium, make sure to check out Jay Judas and Peter Dziedzic presenting during today's break out sessions. Their presentation delves into two dynamic topics that can optimize revenue generation. More info on time and location in the graphic below.

GREAT insights to be gained from this webinar next week, please register and tune in!

If you want to improve your financial literacy, it’s time to have conversations about money. By understanding the things that make up your financial picture, you have the power to take control of your financial future. Contact me and start getting answers to these questions. Click the link to schedule a time to discuss further.

Yesterday, Daré Bioscience, Inc. announced full year 2023 financial results, showing once again that we’ve built the premier company in women’s health with the broadest portfolio of potentially first-in-category product candidates. We made significant strides in 2023 to advance innovative therapies for women and position ourselves well for the milestones to come in 2024. In 2023 alone, we announced the first shipment of XACIATO™ in connection with its launch in the United States, had 15 interactions with the FDA across six product candidates / indications, commenced the pivotal Phase 3 study for our hormone-free monthly intravaginal contraceptive candidate Ovaprene, successfully completed the Phase 2b study of our investigational Sildenafil Cream product in female sexual arousal disorder and the DARE-PDM1 vaginal diclofenac for menstrual pain Phase 1 study, and received IND clearance for DARE-VVA1, our hormone-free treatment for sexual pain. I’m also excited about the increased attention that women’s health has received more broadly since the White House announced the first-ever initiative on women’s health research in November, an effort led by First Lady Dr. Jill Biden and the White House Gender Policy Council, which emphasized that to “achieve scientific breakthroughs and strengthen our ability to prevent, detect, and treat diseases, we have to be bold.” (Oh yes, we do, and we are – and personally, it’s rewarding to see that language given in English, “Daré” means “to be bold”!) I’ve also had the pleasure of attending in person both the ARPA-H announcement with Dr. Biden in Boston last month and the signing of the executive order at the White House just last week – all moments that remind me just how much we can accomplish by bringing focus and investment to the entire ecosystem to boldly innovate for women. Our achievements, coupled with these recent industry developments, underscore what a fantastic time it is to be working in women’s health, and the significant opportunity in this space. But most importantly, our achievements in 2023 demonstrate that our approach to accelerating clinical development works, and that our leading programs have disruptive potential in the conditions and populations they aim to treat. None of these successes would have been possible without the Daré team’s unwavering commitment to advancing innovation for women’s health, which continues to drive our progress. I look forward to building on this momentum as we continue to accelerate therapies that increase options, improve outcomes, and offer convenience for women’s most persistent unmet needs. Learn more about our financial results and company update here: https://bit.ly/3VwTx33

Attention #Investors! 📢 Registration for our Investor Select Conference on February 1st is now open! Click below to sign up and lock in your 1x1 meetings today. 🔒 #irchat #investorrelations #finance #1x1meetings #lythamselect2024

We would like to invite you to a very special webinar featuring growth and income strategies for your clients age 50-plus. (CFP and I&WI CE Credits approved) #financialplanning #investing Arne Noack Jeff Cullen Matt Kaufman, CETF® Click the link below to register.

One of the many nuggets of insight from Davina Rooney during our recent panel discussion, as we gave our industry predictions for the year ahead. This snippet is from last week’s webinar, ‘Commercial Property Forecast: Expert Predictions for FY25’. Check out the full recording at https://lnkd.in/ewCtjX-9